Expected Moves

Market pricing of expected environmental policy shifts under President Trump, specifically regarding EPA mandates that drive BioRem's pollution control equipment sales.

Q3 earnings print with intense focus on reconciling the massive divergence between impressive net income growth and deeply negative operating cash flows.

Anticipated operational update detailing Q4 order intake and early FY2027 backlog visibility for large-scale biofiltration systems.

Audited FY26 financials and Q4 print. Investors will demand clear evidence that top-line momentum (66% YoY) is yielding durable, high-margin conversion.

Q1 print providing the initial look at 2027 project execution and capital expenditure normalization.